No Data
Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Cliff Asness' Stock Picks With Huge Upside Potential
Neurocrine Biosciences Announces Initiation Of Phase 3 Registrational Program for NBI-1117568 As Potential Treatment For Adults With Schizophrenia
Express News | Neurocrine Biosciences Initiates Phase 3 Registrational Program for Nbi-1117568 as Potential Treatment for Adults With Schizophrenia
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $192
Earnings Preview: NBIX to Report Financial Results Post-market on May 05
BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $179